PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
By Holly Campbell | March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt patients’ ability...
Read More
Addressing barriers that inhibit value-based contracts
By Katie Koziara | February 21, 2020
With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we...
Read More
Fact Check: HCCI analysis overstates medicine spending and prices
By Katie Koziara | February 19, 2020
A recent analysis from the Health Care Cost Institute (HCCI) on health care spending overestimates medicine spending and pricing and mischaracterizes the true drivers of health care spending in...
Read More
Cancer medicines cost twice as much at hospitals, study finds
By Katie Koziara | January 21, 2020
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research...
Read More
Nearly 50% of brand medicine spending goes to the supply chain and others
By Holly Campbell | January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...
Read More
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
By Holly Campbell | December 6, 2019
According to new data from the National Health Expenditures (NHE), retail medicine prices declined by 1% and retail medicine spending grew just 2.5% in 2018. To put that in context, hospital...
Read More
More evidence that medicine prices are growing at slowest rate in decades
By Holly Campbell | October 4, 2019
This week the White House Council of Economic Advisers (CEA) released yet another report showing that medicine prices are growing at the slowest rate in decades. The report, “Measuring...
Read More
The truth about the marketing and promotion of medicines
By Holly Campbell | October 3, 2019
Despite what critics say, the U.S. biopharmaceutical industry spends three times more on the research and development (R&D) of new treatments and cures than on the marketing and promotion of...
Read More
Survey shows out-of-pocket costs top health care concern for voters
By Holly Campbell | October 2, 2019
A recent national survey of 800 registered voters conducted by Public Opinion Strategies shows that health insurance premiums, deductibles and copays are the top health care concerns for...
Read More
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
By Katie Koziara | September 10, 2019
A new study, conducted by the Partnership for Health Analytic Research (PHAR), found that hospitals retained 91% of the total profit on physician-administered medicines in the commercial market...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
